Articles

‘Knock on Wood’ campaign boosts Farm Bureau brand

The torrent of competitors’ humorous TV commercials forced Indiana Farm Bureau Insurance to roll out its own campaign. So far, its “Knock on Wood” shtick is said to have boosted brand awareness in urban markets by 12 percent, as measured by social media chatter.

Read More

St. Vincent adds Bloomington hospital to its fold

Indianapolis-based St. Vincent Health will manage operations at Monroe Hospital in Bloomington under an agreement announced on Tuesday. Monroe gives St. Vincent a line of hospitals stretching from Indianapolis to Bedford and even farther south to Salem and Evansville.

Read More

Two more clinical trials go against Lilly

In the midst of Eli Lilly and Co.’s surprisingly positive news about its experimental Alzheimer’s drug, the company suffered two other setbacks with former stars of its pipeline.

Read More

Drug company makes $181M settlement with states

Janssen Pharmaceuticals Inc. and parent company Johnson & Johnson on Thursday announced a $181 million settlement with 36 states, including Indiana, and the District of Columbia over charges of marketing anti-psychotic drugs for non-approved uses.

Read More

Departing CEO Braly due to get $15M exit package

WellPoint Inc. is expected to give about $15 million in cash, stock and benefits to former CEO Angela Braly on her way out the door, based on the terms of a separation agreement filed by the company Wednesday morning. And the payout could be even more lucrative based on the company’s future stock price.

Read More

Salmonella at Indiana farm matches outbreak strain

A southwestern Indiana cantaloupe farm is the source of at least some of the salmonella responsible for an outbreak that sickened people in 21 states and killed two Kentucky residents, the Food and Drug Administration said Tuesday.

Read More

Does Lilly have enough on Alzheimer’s drug?

After Eli Lilly and Co. found a “glimmer of hope” in its test of its experimental Alzheimer’s drug, doctors and stock analysts generally concluded the company needs to conduct another long clinical trial to prove the drug’s effect. But one stock analyst thinks Lilly already has what it needs to ask for approval for its drug.

Read More